The addition of everolimus to fulvestrant was associated with more than a doubling of progression-free survival in women with metastatic hormone receptor–positive, HER2-negative breast cancer who were resistant to aromatase inhibitor therapy.
Second-line treatment with osimertinib resulted in significantly better progression-free survival compared with chemotherapy alone in patients with EGFR-T790M positive NSCLC, according to the results of the AURA3 trial.
In this interview we discuss breast cancer prevention and risk assessments, including the questions these assessments aim to answer, what classifies someone as average or high risk, and appropriate next steps for patients who fall in these categories.
This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.
Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.